USA - NASDAQ:MITO - US85789A1051 - ADR
Taking everything into account, MITO scores 1 out of 10 in our fundamental rating. MITO was compared to 538 industry peers in the Biotechnology industry. Both the profitability and financial health of MITO have multiple concerns. MITO has a expensive valuation and it also scores bad on growth.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -143.5% | ||
ROE | N/A | ||
ROIC | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | N/A | ||
PM (TTM) | N/A | ||
GM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | -0.26 | ||
Debt/FCF | N/A | ||
Altman-Z | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 3.68 | ||
Quick Ratio | 3.68 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | N/A | ||
EV/EBITDA | -0.07 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
NASDAQ:MITO (11/15/2022, 8:00:01 PM)
0.32
0 (-1.36%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A | ||
P/S | N/A | ||
P/FCF | N/A | ||
P/OCF | N/A | ||
P/B | N/A | ||
P/tB | N/A | ||
EV/EBITDA | -0.07 |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -143.5% | ||
ROE | N/A | ||
ROCE | N/A | ||
ROIC | N/A | ||
ROICexc | N/A | ||
ROICexgc | N/A | ||
OM | N/A | ||
PM (TTM) | N/A | ||
GM | N/A | ||
FCFM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | -0.26 | ||
Debt/FCF | N/A | ||
Debt/EBITDA | N/A | ||
Cap/Depr | N/A | ||
Cap/Sales | N/A | ||
Interest Coverage | N/A | ||
Cash Conversion | N/A | ||
Profit Quality | N/A | ||
Current Ratio | 3.68 | ||
Quick Ratio | 3.68 | ||
Altman-Z | N/A |